rocbrutinib

LP-168, also called rocbrutinib, is a fourth-generation BTK inhibitor from Newave Pharmaceutical (Guangzhou Lupeng) designed to hit wild-type BTK, the C481-mutant forms that drive resistance to ibrutinib/acalabrutinib/zanubrutinib, AND the T474I gatekeeper mutation that drives resistance to pirtobrutinib [1][2][11]. The generational ladder in this class runs ibrutinib (1st, covalent) → acalabrutinib/zanubrutinib (2nd, cleaner covalent) → pirtobrutinib (3rd, non-covalent) → rocbrutinib (4th, dual-mode covalent + non-covalent). The node still tags this as Phase 1 from the original dose-finding study NCT04775745, but the program has materially advanced: NMPA accelerated approval in China on June 4, 2026 for relapsed/refractory mantle cell lymphoma (based on the ROCK-1 Phase 2 registrational study) [12], and two global Phase 3 trials are now enrolling - ROCKET-CLL head-to-head against pirtobrutinib in previously BTKi-treated CLL/SLL [3] and a Phase 3 in R/R MCL against investigator's choice BTKi [4]. The commercial question: can a Chinese-sponsored asset with a credible mechanistic differentiator land a Western win in a market where Loxo/Lilly's pirtobrutinib (Jaypirca) already owns the post-covalent-BTKi niche?

Rocbrutinib is now APPROVED in China for R/R MCL (NMPA accelerated approval June 4, 2026, after ≥2 prior systemic therapies including a BTKi) [12]; it is not approved in the US, EU, or anywhere else. The seed trial NCT04775745 is a Phase 1 dose-escalation in R/R B-cell malignancies, still active toward n=60, with MTD as the primary endpoint [5]. An ASH 2024 update from the Phase 1 CLL gatekeeper cohort (n=10 patients with T474 BTK mutations, median variant allele frequency 15.6%) reported a 77.8% overall response rate (7/9 evaluable, all PR or PR-with-lymphocytosis) at median 14 months follow-up [11] - the disclosed signal that justified moving into registrational studies. A Phase 2 in R/R MCL (NCT05716087, n=62) is active and not recruiting [6]; the ROCK-1 Phase 2 generated the dataset that supported the NMPA filing. Two Phase 3 trials are now open: ROCKET-CLL (NCT07342478, n=306) randomizes covalent-BTKi-pretreated CLL/SLL patients between rocbrutinib and pirtobrutinib, with IRC-assessed PFS as primary [3]. NCT07377578 (n=394) tests rocbrutinib vs investigator's choice BTKi in R/R MCL [4]. A drug-drug interaction study with itraconazole and rifampin (NCT07374224) supports the regulatory package [7]. No FDA breakthrough, fast track, orphan, or accelerated approval designations are on file in the US. Picking pirtobrutinib as comparator in CLL is striking: Newave is betting the global program on beating, not matching, the current best-in-class non-covalent BTKi.

BTK (Bruton's tyrosine kinase) is an enzyme inside B cells that relays survival and proliferation signals from the B-cell receptor, the antenna B cells use to sense antigens [8]. In chronic lymphocytic leukemia and mantle cell lymphoma, malignant B cells become addicted to that signal. Block BTK and the cancer cells stop getting the message to grow. Ibrutinib proved this mechanism, generated multibillion-dollar franchises for AbbVie and Johnson & Johnson, and was followed by cleaner second-generation covalent inhibitors acalabrutinib and zanubrutinib [9]. All three bind covalently to cysteine 481 in the BTK active site. Covalent inhibitors work like superglue: they form a permanent chemical bond to cysteine 481 and shut BTK off indefinitely. When tumors mutate that cysteine to serine (C481S), the superglue has nothing to stick to and the drug stops working - patients relapse [1]. Non-covalent inhibitors like pirtobrutinib work more like a tight-fitting plug: no permanent bond, so the C481 mutation doesn't matter [2]. But pirtobrutinib has its own resistance route - second-site mutations at T474 (the gatekeeper residue), which sit in the binding pocket and physically push the plug out. Rocbrutinib's pitch is that it does all three jobs at once: it locks covalently onto BTK when C481 is intact (giving strong suppression in covalent-BTKi-naive patients), it switches to non-covalent binding at an adjacent site when C481 is mutated (the same trick pirtobrutinib uses), AND it covalently engages T474I-mutant BTK at a separate residue, covering a resistance population where pirtobrutinib has limited activity [11]. The target itself is unambiguously validated. Whether this dual/triple-coverage profile produces clinically meaningful separation from pirtobrutinib in the unmutated covalent-BTKi-pretreated population - which is most of the ROCKET-CLL trial - is the unanswered question, and the Phase 3 design is built to answer it.

NCT04775745 is the original Phase 1, oral rocbrutinib in adults with R/R B-cell malignancies (CLL, MCL, other NHL), standard 3+3 dose escalation toward MTD, with secondary endpoints including ORR and PK [5]. Run by Newave at US and Chinese sites, n=60. The ASH 2024 disclosure included a dedicated CLL gatekeeper-mutation cohort (T474 BTK mutations) with 77.8% ORR in evaluable patients at 14 months follow-up [11] - the cleanest publicly disclosed proof-of-concept for the T474I differentiation claim. The China R/R MCL registrational ROCK-1 Phase 2 supported the NMPA approval [12]; full ORR/DOR specifics from ROCK-1 have been reported through Chinese conferences but are not yet in a peer-reviewed Western journal. The more consequential global study is ROCKET-CLL (NCT07342478), a 306-patient global Phase 3 randomizing previously covalent-BTKi-treated R/R CLL/SLL patients 1:1 between rocbrutinib and pirtobrutinib, with PFS by independent review as primary [3]. Choosing pirtobrutinib as comparator rather than investigator's choice or chemoimmunotherapy is aggressive: a non-inferiority outcome means nothing commercially against an already-approved drug; only a superior PFS hazard ratio creates a label and a pricing argument in the US. The MCL Phase 3 NCT07377578 uses investigator's choice of BTKi as comparator, a safer design but a less differentiating one [4]. Enrollment status across the registrational program is RECRUITING.

Our model estimates a 29% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and smaller-than-typical enrollment for this phase. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Competitive risk is the dominant failure mode for the US/EU opportunity. Pirtobrutinib is already approved for post-covalent-BTKi CLL and MCL [2], nemtabrutinib is in two Phase 3 trials (BELLWAVE-011 vs ibrutinib/acalabrutinib in untreated CLL, ~1200 pts, currently enrolling) [13], and BTK degraders from Nurix and BeiGene are advancing through Phase 1/2. By the time rocbrutinib reads out ROCKET-CLL the post-covalent niche may have at least three differentiated mechanisms. A non-inferior PFS result against pirtobrutinib produces no US label and no pricing power. Execution risk is real: head-to-head against an approved drug requires hitting a superior PFS hazard ratio, and the enrollment population is the same pool every competitor is fishing in. Safety risk follows the class signature: atrial fibrillation, hypertension, and bleeding have dogged ibrutinib, with the ELEVATE-RR head-to-head showing acalabrutinib has 2.0-, 2.8-, and 1.6-fold lower exposure-adjusted incidence rates than ibrutinib for AF, hypertension, and bleeding respectively [9]; second/third-generation BTKis lowered but did not eliminate these. Rocbrutinib's combined covalent + non-covalent binding could in principle widen off-target exposure; the full Western-disclosed safety profile is still thin. Commercial risk is structural: Newave/Guangzhou Lupeng has no US commercial infrastructure, and even a clean Phase 3 win likely requires a Western partnership deal to monetize outside China. Patent and IP scrutiny on China-originated oncology compounds is elevated relative to two years ago.

Worth watching, with three concrete data points to track. (1) The most probable near-term commercial path is the China NMPA approval already in hand for R/R MCL [12], and label expansion into Chinese CLL is the realistic next milestone - China is the world's second-largest pharma market with a substantial and less-saturated CLL post-covalent population than the US. A Chinese commercial ramp would validate the program and likely accelerate Western partnership discussions, which is the more important investment signal than the global Phase 3 readouts. (2) ASH 2026 is a Phase 2 MCL checkpoint (potential updated data from NCT05716087 [6]) - NOT a ROCKET-CLL readout. (3) ROCKET-CLL (NCT07342478) is the global commercial inflection but is still in early enrollment; given PFS as primary endpoint, median PFS on pirtobrutinib of ~19 months in this population, and n=306, a first interim is realistically a 2028+ event barring accelerated accrual. A PFS hazard ratio under 0.7 versus pirtobrutinib would be a genuine signal and would change the competitive picture in post-covalent CLL. A hazard ratio between 0.85 and 1.0 effectively kills the US commercial case even if the trial technically reads as non-inferior. Newave is a private Chinese biotech without public financials, so commercial intelligence requires watching for partnership announcements or licensing deals with a Western pharma; absent that, treat this as a China-revenue play with global optionality, not a near-term US story. The PoS model's 9.1% is too low: the program has already cleared the hardest gate (an approval, in China) and the BTK target is one of the best-validated in heme oncology.